Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Maker of Antibiotic-Free Animal Supplement Lands First Order from Mexico
News Update

Share on Stocktwits


This new market is a significant one for Avivagen.

Avivagen Inc. (VIV:TSX.V; VIVXF:OTCQB) announced in a news release it received its first order from Mexico for two of its products and is finalizing sales agreements with the buyer, Industrias Melder.

A feed miller that sells commercial feeds to swine, dairy and poultry producers, Industrias Melder ordered from Avivagen 350 kilograms of OxC-beta™ Livestock and 1,000 bags of Vivamune. The Jalisco-based company intends to sell Vivamune through Super Pet, its chain of retail pet stores.

The relationship between the two entities extends further, as Industrias Melder is doing confirmatory testing of OxC-beta Livestock in different species. This development came about after Avivagen presented the product at a seminar series put on by Mexico's Association of Food Producers. The event was well attended by feed and livestock manufacturers.

"We are very excited to announce our first purchase orders of OxC-beta™ Livestock and Vivamune in Mexico, paving the way for continued distribution and acceptance of our technology in major feed markets worldwide,” said Kym Anthony, CEO of Avivagen. “With annual feed sales of more than 36 million tonnes, compared with 18.2 million for The Philippines, 20.2 million for Thailand and 21.6 million for Canada, Mexico represents a fast-growing and important market for OxC-beta™ Livestock. We are confident that, as in other markets around the world, the demand for OxC-beta™ Livestock in Mexico and throughout North America will rapidly expand."


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.

Want to read more about Nutraceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe